CHAMBERLAIN UNIVERSITY – NR 546 FINAL EXAM
– QUESTIONS AND ANSWERS | 2026/2027 LATEST
UPDATE
SECTION 1: MOOD DISORDERS AND
NEUROBIOLOGY
Questions 1–13
1. Which neurotransmitter network is most directly associated with the neurobiological
regulation of mood and commonly targeted by antidepressant therapy?
A) Serotonin, norepinephrine, and dopamine pathways
B) Acetylcholine, histamine, and glycine pathways
C) Glutamate, melatonin, and acetylcholine pathways
D) GABA, histamine, and orexin pathways
Correct Answer: Serotonin, norepinephrine, and dopamine pathways
Rationale: Serotonin, norepinephrine, and dopamine are central neurotransmitters involved in
mood regulation and are important targets of many antidepressant medications. Dysfunction in
these systems can contribute to depressive symptoms involving mood, motivation, cognition, and
energy. Understanding these networks helps the PMHNP connect medication mechanisms with
clinical symptom domains.
2. What feature most strongly distinguishes bipolar disorder from unipolar major
depressive disorder?
A) Presence of insomnia during depressive episodes
B) A history of manic or hypomanic episodes
C) Reduced appetite during periods of depression
D) Difficulty concentrating during mood episodes
Correct Answer: A history of manic or hypomanic episodes
Rationale: Bipolar disorders are defined by episodes of mania or hypomania, depending on the
specific diagnosis, in addition to depressive episodes in many cases. Insomnia, appetite changes,
and impaired concentration can occur in both bipolar depression and major depressive disorder.
Correct identification is essential because antidepressant monotherapy can be problematic in
bipolar illness.
3. Which clinical feature is most characteristic of mania rather than hypomania?
A) Mildly increased productivity without impairment
B) Brief elevation of mood without functional consequences
,C) Marked impairment, hospitalization, or psychosis
D) Stable sleep and unchanged judgment
Correct Answer: Marked impairment, hospitalization, or psychosis
Rationale: Mania is sufficiently severe to cause marked functional impairment, require
hospitalization, or include psychotic features. Hypomania involves a distinct period of elevated
or irritable mood and increased activity but does not produce the marked impairment
characteristic of mania. This distinction is fundamental when differentiating bipolar I from
bipolar II disorder.
4. A PMHNP is selecting an initial pharmacologic treatment for uncomplicated major
depressive disorder. Which medication class is generally considered a first-line option?
A) SSRI
B) MAOI
C) Typical antipsychotic
D) Barbiturate
Correct Answer: SSRI
Rationale: Selective serotonin reuptake inhibitors are commonly used as first-line
pharmacologic treatment for major depressive disorder because they have established efficacy
and generally favorable tolerability. MAOIs are effective but require more restrictive
prescribing and interaction precautions. Antipsychotics and barbiturates are not routine first-
line monotherapies for uncomplicated major depression.
5. Why might bupropion be particularly attractive when depressive symptoms include low
energy and concern about sexual adverse effects?
A) It strongly blocks muscarinic receptors
B) It primarily increases GABA activity
C) It inhibits norepinephrine and dopamine reuptake
D) It directly stimulates opioid receptors
Correct Answer: It inhibits norepinephrine and dopamine reuptake
Rationale: Bupropion is classified as a norepinephrine-dopamine reuptake inhibitor and can
improve energy, motivation, and alertness. It is also generally associated with fewer sexual
adverse effects than many serotonergic antidepressants. However, seizure risk must be
considered, particularly in individuals with conditions that lower seizure threshold.
6. Which antidepressant characteristic makes fluoxetine useful for someone who frequently
forgets daily doses?
A) Extremely short half-life
B) Long half-life and active metabolite
C) Complete elimination through the kidneys within hours
D) Immediate therapeutic action after one dose
,Correct Answer: Long half-life and active metabolite
Rationale: Fluoxetine has a relatively long half-life and an active metabolite, norfluoxetine,
which contributes to prolonged exposure. This pharmacokinetic profile can make occasional
missed doses less problematic than with shorter-acting antidepressants. It does not mean
adherence is unnecessary, because consistent administration remains important for optimal
treatment.
7. Which medication requires particular caution because of the risk of serotonin syndrome
when combined with other serotonergic agents?
A) Escitalopram
B) Bupropion
C) Guanfacine
D) Memantine
Correct Answer: Escitalopram
Rationale: Escitalopram is an SSRI that increases serotonergic activity. Combining it with other
medications that substantially increase serotonin can increase the risk of serotonin toxicity,
characterized by findings such as agitation, autonomic instability, hyperreflexia, and clonus.
Careful medication reconciliation is therefore essential before initiating or changing
serotonergic therapy.
8. A patient receiving sertraline reports modest improvement after four weeks and no
significant adverse effects. What is the most appropriate general strategy when the dose
remains below the therapeutic range?
A) Immediately discontinue treatment
B) Add lithium regardless of diagnosis
C) Consider titrating the SSRI while monitoring response and tolerability
D) Replace the medication with an MAOI
Correct Answer: Consider titrating the SSRI while monitoring response and tolerability
Rationale: Partial improvement with good tolerability may support continuing the same
antidepressant while optimizing the dose. Antidepressant treatment requires adequate dose and
duration before declaring nonresponse. Abrupt switching or adding unrelated medications
without assessing adherence, dose, duration, and diagnosis can lead to unnecessary treatment
complexity.
9. Which adverse effect is particularly associated with serotonergic antidepressants during
initiation or dose escalation?
A) Increased anxiety or activation
B) Severe hypothermia in most users
C) Permanent hearing loss
D) Complete loss of appetite in every patient
, Correct Answer: Increased anxiety or activation
Rationale: Some individuals experience transient anxiety, restlessness, gastrointestinal
symptoms, or activation after starting an SSRI or SNRI. These effects may improve as treatment
continues, but significant agitation or worsening symptoms require clinical assessment.
Counseling before treatment helps patients distinguish expected early effects from potentially
dangerous reactions.
10. What is the primary pharmacologic concern when combining an MAOI with an SSRI?
A) Severe hypoglycemia
B) Serotonin syndrome
C) Acute iron deficiency
D) Reduced acetylcholine production
Correct Answer: Serotonin syndrome
Rationale: MAOIs inhibit the breakdown of monoamines, while SSRIs increase serotonergic
signaling. Combining them can produce excessive serotonin activity and potentially life-
threatening serotonin syndrome. Appropriate washout periods and careful medication
reconciliation are therefore essential when transitioning between serotonergic antidepressants
and MAOIs.
11. Which medication is associated with a clinically important risk of serious rash,
including Stevens-Johnson syndrome?
A) Lamotrigine
B) Venlafaxine
C) Fluoxetine
D) Buspirone
Correct Answer: Lamotrigine
Rationale: Lamotrigine carries a well-established risk of serious cutaneous reactions, including
Stevens-Johnson syndrome and toxic epidermal necrolysis. Slow dose titration helps reduce this
risk. Patients should be instructed to report significant rash promptly rather than continuing the
medication without evaluation.
12. Which pharmacologic agent is commonly used as a mood stabilizer and requires
monitoring of serum concentrations, renal function, thyroid function, and hydration
status?
A) Lithium
B) Fluoxetine
C) Methylphenidate
D) Ramelteon
Correct Answer: Lithium
– QUESTIONS AND ANSWERS | 2026/2027 LATEST
UPDATE
SECTION 1: MOOD DISORDERS AND
NEUROBIOLOGY
Questions 1–13
1. Which neurotransmitter network is most directly associated with the neurobiological
regulation of mood and commonly targeted by antidepressant therapy?
A) Serotonin, norepinephrine, and dopamine pathways
B) Acetylcholine, histamine, and glycine pathways
C) Glutamate, melatonin, and acetylcholine pathways
D) GABA, histamine, and orexin pathways
Correct Answer: Serotonin, norepinephrine, and dopamine pathways
Rationale: Serotonin, norepinephrine, and dopamine are central neurotransmitters involved in
mood regulation and are important targets of many antidepressant medications. Dysfunction in
these systems can contribute to depressive symptoms involving mood, motivation, cognition, and
energy. Understanding these networks helps the PMHNP connect medication mechanisms with
clinical symptom domains.
2. What feature most strongly distinguishes bipolar disorder from unipolar major
depressive disorder?
A) Presence of insomnia during depressive episodes
B) A history of manic or hypomanic episodes
C) Reduced appetite during periods of depression
D) Difficulty concentrating during mood episodes
Correct Answer: A history of manic or hypomanic episodes
Rationale: Bipolar disorders are defined by episodes of mania or hypomania, depending on the
specific diagnosis, in addition to depressive episodes in many cases. Insomnia, appetite changes,
and impaired concentration can occur in both bipolar depression and major depressive disorder.
Correct identification is essential because antidepressant monotherapy can be problematic in
bipolar illness.
3. Which clinical feature is most characteristic of mania rather than hypomania?
A) Mildly increased productivity without impairment
B) Brief elevation of mood without functional consequences
,C) Marked impairment, hospitalization, or psychosis
D) Stable sleep and unchanged judgment
Correct Answer: Marked impairment, hospitalization, or psychosis
Rationale: Mania is sufficiently severe to cause marked functional impairment, require
hospitalization, or include psychotic features. Hypomania involves a distinct period of elevated
or irritable mood and increased activity but does not produce the marked impairment
characteristic of mania. This distinction is fundamental when differentiating bipolar I from
bipolar II disorder.
4. A PMHNP is selecting an initial pharmacologic treatment for uncomplicated major
depressive disorder. Which medication class is generally considered a first-line option?
A) SSRI
B) MAOI
C) Typical antipsychotic
D) Barbiturate
Correct Answer: SSRI
Rationale: Selective serotonin reuptake inhibitors are commonly used as first-line
pharmacologic treatment for major depressive disorder because they have established efficacy
and generally favorable tolerability. MAOIs are effective but require more restrictive
prescribing and interaction precautions. Antipsychotics and barbiturates are not routine first-
line monotherapies for uncomplicated major depression.
5. Why might bupropion be particularly attractive when depressive symptoms include low
energy and concern about sexual adverse effects?
A) It strongly blocks muscarinic receptors
B) It primarily increases GABA activity
C) It inhibits norepinephrine and dopamine reuptake
D) It directly stimulates opioid receptors
Correct Answer: It inhibits norepinephrine and dopamine reuptake
Rationale: Bupropion is classified as a norepinephrine-dopamine reuptake inhibitor and can
improve energy, motivation, and alertness. It is also generally associated with fewer sexual
adverse effects than many serotonergic antidepressants. However, seizure risk must be
considered, particularly in individuals with conditions that lower seizure threshold.
6. Which antidepressant characteristic makes fluoxetine useful for someone who frequently
forgets daily doses?
A) Extremely short half-life
B) Long half-life and active metabolite
C) Complete elimination through the kidneys within hours
D) Immediate therapeutic action after one dose
,Correct Answer: Long half-life and active metabolite
Rationale: Fluoxetine has a relatively long half-life and an active metabolite, norfluoxetine,
which contributes to prolonged exposure. This pharmacokinetic profile can make occasional
missed doses less problematic than with shorter-acting antidepressants. It does not mean
adherence is unnecessary, because consistent administration remains important for optimal
treatment.
7. Which medication requires particular caution because of the risk of serotonin syndrome
when combined with other serotonergic agents?
A) Escitalopram
B) Bupropion
C) Guanfacine
D) Memantine
Correct Answer: Escitalopram
Rationale: Escitalopram is an SSRI that increases serotonergic activity. Combining it with other
medications that substantially increase serotonin can increase the risk of serotonin toxicity,
characterized by findings such as agitation, autonomic instability, hyperreflexia, and clonus.
Careful medication reconciliation is therefore essential before initiating or changing
serotonergic therapy.
8. A patient receiving sertraline reports modest improvement after four weeks and no
significant adverse effects. What is the most appropriate general strategy when the dose
remains below the therapeutic range?
A) Immediately discontinue treatment
B) Add lithium regardless of diagnosis
C) Consider titrating the SSRI while monitoring response and tolerability
D) Replace the medication with an MAOI
Correct Answer: Consider titrating the SSRI while monitoring response and tolerability
Rationale: Partial improvement with good tolerability may support continuing the same
antidepressant while optimizing the dose. Antidepressant treatment requires adequate dose and
duration before declaring nonresponse. Abrupt switching or adding unrelated medications
without assessing adherence, dose, duration, and diagnosis can lead to unnecessary treatment
complexity.
9. Which adverse effect is particularly associated with serotonergic antidepressants during
initiation or dose escalation?
A) Increased anxiety or activation
B) Severe hypothermia in most users
C) Permanent hearing loss
D) Complete loss of appetite in every patient
, Correct Answer: Increased anxiety or activation
Rationale: Some individuals experience transient anxiety, restlessness, gastrointestinal
symptoms, or activation after starting an SSRI or SNRI. These effects may improve as treatment
continues, but significant agitation or worsening symptoms require clinical assessment.
Counseling before treatment helps patients distinguish expected early effects from potentially
dangerous reactions.
10. What is the primary pharmacologic concern when combining an MAOI with an SSRI?
A) Severe hypoglycemia
B) Serotonin syndrome
C) Acute iron deficiency
D) Reduced acetylcholine production
Correct Answer: Serotonin syndrome
Rationale: MAOIs inhibit the breakdown of monoamines, while SSRIs increase serotonergic
signaling. Combining them can produce excessive serotonin activity and potentially life-
threatening serotonin syndrome. Appropriate washout periods and careful medication
reconciliation are therefore essential when transitioning between serotonergic antidepressants
and MAOIs.
11. Which medication is associated with a clinically important risk of serious rash,
including Stevens-Johnson syndrome?
A) Lamotrigine
B) Venlafaxine
C) Fluoxetine
D) Buspirone
Correct Answer: Lamotrigine
Rationale: Lamotrigine carries a well-established risk of serious cutaneous reactions, including
Stevens-Johnson syndrome and toxic epidermal necrolysis. Slow dose titration helps reduce this
risk. Patients should be instructed to report significant rash promptly rather than continuing the
medication without evaluation.
12. Which pharmacologic agent is commonly used as a mood stabilizer and requires
monitoring of serum concentrations, renal function, thyroid function, and hydration
status?
A) Lithium
B) Fluoxetine
C) Methylphenidate
D) Ramelteon
Correct Answer: Lithium
